Nuveen Asset Management LLC Has $2.11 Million Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Nuveen Asset Management LLC boosted its holdings in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 42.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,432,404 shares of the biotechnology company's stock after buying an additional 425,484 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.21% of OPKO Health worth $2,106,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Millennium Management LLC grew its holdings in OPKO Health by 85.3% in the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock worth $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in shares of OPKO Health by 143.6% during the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock valued at $3,746,000 after purchasing an additional 1,502,342 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of OPKO Health in the 4th quarter worth $2,082,000. Norges Bank purchased a new position in OPKO Health during the 4th quarter worth $1,657,000. Finally, Marshall Wace LLP grew its stake in OPKO Health by 856.5% during the 4th quarter. Marshall Wace LLP now owns 921,487 shares of the biotechnology company's stock worth $1,355,000 after buying an additional 825,143 shares during the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Stock Down 0.7%

OPKO Health stock traded down $0.01 during trading on Friday, reaching $1.36. The stock had a trading volume of 2,325,566 shares, compared to its average volume of 3,843,752. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 52-week low of $1.19 and a 52-week high of $2.04. The stock has a market cap of $1.08 billion, a PE ratio of -7.16 and a beta of 1.39. The business has a 50 day moving average price of $1.38 and a 200 day moving average price of $1.53.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $149.90 million during the quarter, compared to analysts' expectations of $163.13 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The firm's revenue for the quarter was down 13.7% on a year-over-year basis. On average, analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on OPK. HC Wainwright reissued a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. JPMorgan Chase & Co. began coverage on OPKO Health in a research report on Friday, April 25th. They set a "neutral" rating for the company. Barrington Research reissued an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a report on Thursday, May 1st. Finally, Wall Street Zen cut OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $2.75.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the stock in a transaction on Friday, March 28th. The stock was bought at an average price of $1.70 per share, with a total value of $255,000.00. Following the completion of the transaction, the chief executive officer now directly owns 213,651,448 shares of the company's stock, valued at $363,207,461.60. The trade was a 0.07% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders bought 700,000 shares of company stock valued at $1,123,000. 49.69% of the stock is owned by insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.